Dr. Kathleen Anne Mannava, MD

Dr. Mannava practices at Strong Memorial Hospital in Rochester, New York, part of University of Rochester Medical Center.

Dr. Mannava's NPI, 1427284488, was assigned on June 4, 2009. Dr. Mannava holds New York license 289437.

Dr. Mannava's primary practice is Strong Memorial Hospital, at 601 Elmwood Ave, Rochester, NY 14642 in Monroe County. The practice phone is (585) 275-2121.

Dr. Mannava's primary practice is Strong Memorial Hospital in Rochester, New York, part of University of Rochester Medical Center. Dr. Mannava is also affiliated with F.F. Thompson Hospital. The medical group on file is University of Rochester Medical Faculty Group (URMFG). Dmand AI also links Dr. Mannava to 3 more hospitals, 6 medical groups and 5 group practices and clinics, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Mannava practices, 10 sites in all. Vendor and product names are available with a free account.

Dermatology is Dr. Mannava's primary specialty in the NPI Registry, under taxonomy code 207N00000X. Dr. Mannava is licensed in New York.

CMS data shows 3,018 Medicare services from Dr. Mannava across 17 procedure codes in 2024, for 1,310 Medicare patients. Medicare paid $81,824 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 1,310 Medicare patients who saw Dr. Mannava in 2024. The largest group is 65 to 74, with 525 patients. 75% of them have high cholesterol, and 73% have high blood pressure. 13% are also on Medicaid. Their average risk score is 1.27, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Mannava's median patient age at 70, with 50% women.

In 2024, Dr. Mannava wrote 121 Medicare Part D claims for 39 patients. 64% of them were for generic drugs. CMS names the drug for 38 of them, across 1 drug with 11 or more claims each, at $134,277 in total drug cost. In 2023, CMS named 148 claims across 8 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 90 out of 100 for Dr. Mannava for performance year 2024, reported as part of a group. Dr. Mannava accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS counts 450 procedures of removal of skin lesions by Dr. Mannava, more than 85% of the clinicians it reports for that procedure.

Dmand AI links 22 papers to Dr. Mannava, published from 2012 to 2025. 2024 was the busiest year, with 4. The most frequent topics are Skin Neoplasms, Biopsy and Diagnosis, Differential. Dr. Mannava has published most often in JAAD Case Rep. Dr. Mannava's most frequent co-authors are Sandeep Mannava, MD, PhD, Glynis A. Scott, MD and Nathaniel Josef Jellinek, MD.

CMS Open Payments shows 4 general payments to Dr. Mannava from 4 drug and device companies from 2016 to 2018. Food and beverage make up the largest share, 100% of the total. Galderma Laboratories, L.P. paid the most, $68.